Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients

Transplantation

Volumn 78, Issue 7, 2004, Pages 964-965

  Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD8 ANTIGEN; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT;

AGED; CHIMERA; CLINICAL PROTOCOL; COMPETITIVE INHIBITION; CYTOLYSIS; DENDRITIC CELL; DISEASE SEVERITY; DRUG DOSE REGIMEN; ERADICATION THERAPY; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; IONIZING RADIATION; MAXIMUM TOLERATED DOSE; MORBIDITY; MORTALITY; NATURAL KILLER CELL; NONMYELOABLATIVE CONDITIONING REGIMEN; NOTE; OUTCOMES RESEARCH; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING REGIMEN; RELAPSE; STEM CELL TRANSPLANTATION; TOXICITY; TREATMENT INDICATION; TUMOR CELL;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 6344251603     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000129810.77790.EF     Document Type: Note

References (6)

1. Le Blanc K, Remberger M, Uzunel M, et al. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004; 78: 1014.
2. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 1996; 87: 2195.
3. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531.
4. Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998; 91: 756.
5. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412.
6. Prigozhina T, Gurevitch O, Slavin S. Non-myeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol 1999; 27: 1503.